MOUNJARO® (TIRZEPATIDE), THE FIRST AND ONLY SINGLE MOLECULE GIP AND GLP-1 RECEPTOR AGONIST FOR THE TREATMENT OF ADULTS WITH TYPE 2 DIABETES IS NOW AVAILABLE IN CANADA – Yahoo Finance